Crystalys Therapeutics Secures $205 Million Series A to Advance Global Phase 3 Gout Program

Crystalys Therapeutics has shared an update.

The company was highlighted in Fred Grier’s Business of San Diego review as one of the largest venture financings in the region for 2025, based on its $205 million Series A round. The capital is earmarked to fund global Phase 3 development of dotinurad, a next-generation URAT1 inhibitor targeting unmet medical need in gout.

For investors, the size of the Series A round signals substantial institutional confidence in Crystalys Therapeutics’ lead asset and development strategy. Funding at this scale should provide a multi-year runway to advance late-stage clinical trials, potentially positioning the company for value inflection events tied to Phase 3 data readouts and future regulatory milestones. If Phase 3 outcomes are positive, dotinurad could enhance Crystalys’s competitive position in the gout treatment market, where demand is driven by chronic disease prevalence and limitations of existing therapies. The company’s inclusion among San Diego’s largest financings also underscores its visibility within the regional life sciences ecosystem, which may support future partnering or exit opportunities. However, investors should remain aware that late-stage clinical and regulatory risks remain significant until pivotal trial results are available.